FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210578717> ?p ?o ?g. }

• W4210578717 endingPage "12" @default.
• W4210578717 startingPage "1" @default.
• W4210578717 abstract "The human genome encodes two melatonin receptors (MT1 and MT2) that relay melatonin signals to cellular interior. Accumulating evidence has linked melatonin to multiple health benefits, among which its anticancer effects have become well-established. However, the implications of its receptors in lung adenocarcinoma have so far remained incompletely understood.This study aims to investigate the response of the MT1 receptor to melatonin treatment and its dynamic regulation by ubiquitin-specific protease 8 (USP8) in lung adenocarcinoma.The mRNA levels of MT1 and MT2 receptors were analyzed with sequencing data. The expression and localization of the MT1 receptor with melatonin treatment were investigated by immunoblotting, immunofluorescence and confocal microscopy assays. Endocytic deubiquitylases were screened to identify MT1 association. The effects of USP8 were assessed with shRNA-mediated knockdown and small molecule inhibitor. The combined efficacy of melatonin and USP8 suppression was also evaluated using xenograft animal models.Bioinformatic analysis revealed increased expression of the MT1 receptor in lung adenocarcinoma tissues. Melatonin treatment leads to the downregulation of the MT1 receptor in lung adenocarcinoma cells, which is attributed to receptor endocytosis and lysosomal degradation via the canonical endo-lysosomal route. USP8 negatively regulates the endocytic degradation of the MT1 receptor incurred by melatonin exposure and thus protects lung adenocarcinoma cell growth. USP8 suppression by knockdown or pharmacological inhibition effectively deters cancer cell proliferation and sensitizes lung adenocarcinoma cells to melatonin in vitro. Furthermore, USP8 silencing significantly potentiates the anticancer effects of melatonin in xenograft tumor models.The MT1 receptor responds to melatonin treatment and is endocytosed for lysosomal degradation that is counteracted by USP8. The inhibition of USP8 demonstrates tumor-suppressive effects and thus can be exploited as potential therapeutic strategy either as monotherapy or combined therapy with melatonin." @default.
• W4210578717 created "2022-02-08" @default.
• W4210578717 creator A5002059830 @default.
• W4210578717 creator A5009476049 @default.
• W4210578717 creator A5019708503 @default.
• W4210578717 creator A5033549542 @default.
• W4210578717 creator A5035445599 @default.
• W4210578717 creator A5037472620 @default.
• W4210578717 creator A5049600050 @default.
• W4210578717 creator A5050588614 @default.
• W4210578717 creator A5055299862 @default.
• W4210578717 creator A5056637168 @default.
• W4210578717 creator A5057869590 @default.
• W4210578717 creator A5066520520 @default.
• W4210578717 creator A5072301177 @default.
• W4210578717 creator A5076749867 @default.
• W4210578717 creator A5082223185 @default.
• W4210578717 creator A5089525692 @default.
• W4210578717 date "2022-11-01" @default.
• W4210578717 modified "2023-09-30" @default.
• W4210578717 title "The ubiquitin-specific protease 8 antagonizes melatonin-induced endocytic degradation of MT1 receptor to promote lung adenocarcinoma growth" @default.
• W4210578717 cites W1573247099 @default.
• W4210578717 cites W1964187078 @default.
• W4210578717 cites W1970826261 @default.
• W4210578717 cites W1972644211 @default.
• W4210578717 cites W2019384027 @default.
• W4210578717 cites W2031333905 @default.
• W4210578717 cites W2035966766 @default.
• W4210578717 cites W2036673125 @default.
• W4210578717 cites W2036811687 @default.
• W4210578717 cites W2041174140 @default.
• W4210578717 cites W2047809194 @default.
• W4210578717 cites W2055361823 @default.
• W4210578717 cites W2066972887 @default.
• W4210578717 cites W2067055276 @default.
• W4210578717 cites W2068807411 @default.
• W4210578717 cites W2075394133 @default.
• W4210578717 cites W2078636414 @default.
• W4210578717 cites W2109337196 @default.
• W4210578717 cites W2117283271 @default.
• W4210578717 cites W2117641259 @default.
• W4210578717 cites W2118225942 @default.
• W4210578717 cites W2119748249 @default.
• W4210578717 cites W2127120815 @default.
• W4210578717 cites W2128551987 @default.
• W4210578717 cites W2139592339 @default.
• W4210578717 cites W2163976491 @default.
• W4210578717 cites W2341012984 @default.
• W4210578717 cites W2517720969 @default.
• W4210578717 cites W2549597224 @default.
• W4210578717 cites W2556932167 @default.
• W4210578717 cites W2559912611 @default.
• W4210578717 cites W2597174991 @default.
• W4210578717 cites W2607129810 @default.
• W4210578717 cites W2615628436 @default.
• W4210578717 cites W2889646458 @default.
• W4210578717 cites W2920920589 @default.
• W4210578717 cites W2973062646 @default.
• W4210578717 cites W2994699197 @default.
• W4210578717 cites W2998576164 @default.
• W4210578717 cites W3018940926 @default.
• W4210578717 cites W3088885461 @default.
• W4210578717 cites W3110500961 @default.
• W4210578717 cites W3128646645 @default.
• W4210578717 cites W3130731342 @default.
• W4210578717 cites W3135961183 @default.
• W4210578717 cites W3137734093 @default.
• W4210578717 doi "https://doi.org/10.1016/j.jare.2022.01.015" @default.
• W4210578717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36328739" @default.
• W4210578717 hasPublicationYear "2022" @default.
• W4210578717 type Work @default.
• W4210578717 citedByCount "1" @default.
• W4210578717 countsByYear W42105787172023 @default.
• W4210578717 crossrefType "journal-article" @default.
• W4210578717 hasAuthorship W4210578717A5002059830 @default.
• W4210578717 hasAuthorship W4210578717A5009476049 @default.
• W4210578717 hasAuthorship W4210578717A5019708503 @default.
• W4210578717 hasAuthorship W4210578717A5033549542 @default.
• W4210578717 hasAuthorship W4210578717A5035445599 @default.
• W4210578717 hasAuthorship W4210578717A5037472620 @default.
• W4210578717 hasAuthorship W4210578717A5049600050 @default.
• W4210578717 hasAuthorship W4210578717A5050588614 @default.
• W4210578717 hasAuthorship W4210578717A5055299862 @default.
• W4210578717 hasAuthorship W4210578717A5056637168 @default.
• W4210578717 hasAuthorship W4210578717A5057869590 @default.
• W4210578717 hasAuthorship W4210578717A5066520520 @default.
• W4210578717 hasAuthorship W4210578717A5072301177 @default.
• W4210578717 hasAuthorship W4210578717A5076749867 @default.
• W4210578717 hasAuthorship W4210578717A5082223185 @default.
• W4210578717 hasAuthorship W4210578717A5089525692 @default.
• W4210578717 hasBestOaLocation W42105787171 @default.
• W4210578717 hasConcept C104317684 @default.
• W4210578717 hasConcept C119056186 @default.
• W4210578717 hasConcept C134018914 @default.
• W4210578717 hasConcept C170493617 @default.
• W4210578717 hasConcept C173396325 @default.
• W4210578717 hasConcept C2778182776 @default.
• W4210578717 hasConcept C2781269140 @default.

• next